Atlas Trials

CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Clinical trial NCT05381662 · UNKNOWN

Trial details

NCT number
NCT05381662
Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Lymphoblastic Leukemia in Remission
Start date
2018-08-02
Primary completion
2024-08-02
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.